|1.||Garcia-Manero, Guillermo: 12 articles (05/2015 - 08/2002)|
|2.||Faderl, Stefan: 10 articles (11/2013 - 08/2002)|
|3.||Kantarjian, Hagop: 9 articles (05/2015 - 01/2003)|
|4.||O'Brien, Susan: 8 articles (05/2015 - 08/2002)|
|5.||Ravandi, Farhad: 8 articles (05/2015 - 02/2007)|
|6.||Cortes, Jorge: 8 articles (05/2015 - 08/2002)|
|7.||Giles, Francis J: 7 articles (02/2013 - 06/2002)|
|8.||Kantarjian, Hagop M: 7 articles (06/2012 - 06/2002)|
|9.||Estey, Elihu H: 6 articles (06/2015 - 06/2002)|
|10.||Cortes, Jorge E: 6 articles (06/2012 - 06/2002)|
|1.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/01/2014 - "Prospective, multicenter, phase II study on reducing the dosage of idarubicin and FLAG for patients younger than 65 years with resistant acute myeloid leukemia: a comparison with a higher dosage trial."
01/01/2004 - "This study has been carried out in our clinic in order to evaluate the efficiency of the acute nonlymphoblastic leukemia protocol which includes idarubicin. "
10/01/1999 - "A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients."
09/01/2014 - "A total of 51 patients with acute myeloid leukemia (AML) induction failure were given elacytarabine-idarubicin as a second induction course. "
10/01/2013 - "The effect of decreased-dose idarubicin for elderly patients with acute myeloid leukemia."
05/01/1988 - "2 out of the 11 anthracycline pretreated patients (91-880 mg/m2) with acute leukemia reached a complete remission undergoing idarubicin p.o. "
04/30/1986 - "This study confirms that idarubicin is effective in acute leukemia also by oral route. "
09/01/2006 - "In this study, 155 leukemia patients were randomly grouped into: 1. test group treated using domestic idarubicin, 2. control group using imported idarubicin. "
09/01/2006 - "To evaluate the safety of domestically produced idarubicin in the treatment of acute leukemia by a multicenter randomized control trial. "
09/01/2006 - "[Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia]."
|3.||Acute Promyelocytic Leukemia
11/01/2002 - "Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up."
05/05/2011 - "From July 1993 to May 2000, 807 genetically proven newly diagnosed acute promyelocytic leukemia patients received ATRA plus idarubicin as induction, followed by 3 intensive consolidation courses. "
10/28/2010 - "After the identification of discrete relapse-risk categories in patients with acute promyelocytic leukemia (APL) receiving all-trans retinoic and idarubicin (AIDA)-like therapies, the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) designed a protocol for newly diagnosed APL (AIDA-2000) in which postremission treatment was risk-adapted. "
04/01/1990 - "Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA."
09/01/2007 - "Could ATRA/Idarubicin treatment of acute promyelocytic leukemia induce the appearance of new clonal cytogenetic abnormalities in patients in complete remission?"
|4.||Breast Neoplasms (Breast Cancer)
05/01/2006 - "This study shows that idarubicin at the dose of 5 mg/day for 21 consecutive days is feasible and effective in elderly breast cancer patients but do not demonstrate an improvement in efficacy. "
02/01/1991 - "Idarubicin is a new anthracycline derivative with therapeutic efficacy in metastatic breast cancer. "
05/01/2006 - "To determine if protracted low-dose oral idarubicin (IDA), feasible in a previous dose-finding study, would result in similar activity and a better toxicity profile in patients with metastatic breast cancer. "
05/01/2006 - "Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring."
06/01/2000 - "Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients."
01/01/2008 - "Idarubicin is a clinically effective synthetic anthracycline analog used in the treatment of several human neoplasms. "
02/01/2015 - "Histopathologic and clinical studies are needed to evaluate idarubicin release around the DEE agents in tumor tissue and to confirm safety and efficacy."
08/01/1990 - "Twenty-one adult patients with refractory solid tumors were treated on a phase I study of idarubicin (4-demethoxydaunorubicin) administered daily for 3 days every 3 weeks. "
01/01/1988 - "In a phase I trial 4-demethoxydaunorubicin (4-dm DNR) was administered as oral capsules once a week to 51 adults with advanced mainly gastrointestinal solid tumors. "
01/01/1988 - "Phase I study of 4-demethoxydaunorubicin by oral route in patients with advanced cancer."
|3.||Etoposide (VP 16)
|6.||Tretinoin (Retinoic Acid)
|2.||Drug Therapy (Chemotherapy)
|3.||Combination Drug Therapy (Combination Chemotherapy)
|4.||Stem Cell Transplantation
|5.||Bone Marrow Transplantation (Transplantation, Bone Marrow)